Cencora, Inc. $COR Stock Position Lowered by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 20.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,000 shares of the company’s stock after selling 5,000 shares during the quarter. Cencora comprises approximately 1.8% of Sivik Global Healthcare LLC’s holdings, making the stock its 9th biggest holding. Sivik Global Healthcare LLC’s holdings in Cencora were worth $6,251,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in COR. Baader Bank Aktiengesellschaft increased its stake in Cencora by 318.5% during the second quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after purchasing an additional 3,300 shares during the last quarter. Focus Partners Wealth boosted its holdings in shares of Cencora by 25.8% in the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after buying an additional 1,171 shares during the period. Acadian Asset Management LLC grew its position in shares of Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the last quarter. Martin Capital Partners LLC raised its stake in Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after acquiring an additional 2,544 shares during the period. Finally, Fiduciary Alliance LLC bought a new position in Cencora in the second quarter worth about $262,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on COR. UBS Group upped their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. JPMorgan Chase & Co. increased their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Robert W. Baird set a $392.00 price objective on shares of Cencora in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $379.50.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 20,317 shares of company stock worth $7,009,260. 10.80% of the stock is owned by company insiders.

Cencora Stock Performance

COR stock opened at $345.99 on Wednesday. The company has a 50-day simple moving average of $349.89 and a 200 day simple moving average of $317.52. The company has a market capitalization of $67.12 billion, a P/E ratio of 43.52, a PEG ratio of 1.62 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a fifty-two week low of $229.36 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. Cencora’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.